As the crisis in anti-infective medicine resistance draws closer, the fundamental problems with the existing model for incentivisation of antibiotic research grow ever clearer. Are there issues here with relevance for drug repurposing R&D?
Numedicus is pleased to announce the licensing of two key pieces of intellectual property, and associated know-how, around the use of an existing glutamate modulator, for the treatment of Rett Syndrome and opiate-induced respiratory depression, to AMO Pharma.
The stakeholders in healthcare in the developed world are conventionally divided into three ‘P’ words: patients, payers and pharmaceutical companies. In addition, there are a couple of other more minor players, namely physicians and pharmacists. Recent developments have, however, dramatically increased the importance and changed the role of one of these participants, the patient community.
Numedicus is please to note the report from PsiOxus, on the outcome of a Phase II trial of MT-102, or s-pindolol, in cancer cachexia. David Cavalla is inventor of this technology (see EP2094254B1).
The recent approval by the FDA of the first non-hormonal product for the treatment of menopausal hot flashes (vasomotor symptoms) in women is interesting for at least two reasons associated with its drug-repurposed basis, one to do with regulation and the other to do with litigation.
Safety and efficacy in medicine is always a balance, and the evidence is increasingly that pharmaceuticals are associated with far more side effects than we currently appreciate. But there are two qualifications regarding safety that are insufficiently appreciated. One is patient group, the other is indication, or therapeutic use. We all know that severe conditions […]